Once daily Busulfan (Bu) and fludarabine (Flu) with allogeneic stem cell transplantation (AlloSCT) in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS): Clinical results and pharmacokinetics.

被引：0
|
作者：
de Lima, M
Madden, T
Couriel, D
Thall, RF
Shahjahan, M
Giralt, S
Anderlini, P
Russell, J
Shpall, EJ
Champlin, RE
Andersson, BS
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantation, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2607
引用
收藏
页码：704A / 705A
页数：2
相关论文
共 50 条
  • [41] EARLY MIXED CHIMERISM DOES NOT ALTER LONG-TERM PROGNOSIS FOR PATIENTS RECEIVING IV BUSULFAN-FLUDARABINE (IV BU-FLU) WITH ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML/MDS
    Tang, X.
    de Lima, M.
    Wei, W.
    Chiattone, A.
    Thall, P. F.
    Medeiros, L. J.
    Rondon, G.
    Shpall, E. J.
    Jones, R. B.
    Nieto, Y.
    Alousi, A.
    Champlin, R. E.
    Andersson, B. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S304 - S304
  • [42] Treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic cell transplantation (HCT).
    Chiattone, A.
    Andersson, B.
    Bashir, Q.
    Landau, D.
    Rondon, G.
    Nieto, Y.
    Al Atrash, G.
    Giralt, S.
    Champlin, R. E.
    De Lima, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Immediate Allogeneic Hematopoietic Cell Transplantation (HCT) in Acute Myeloid Leukemia (AML) Arising From Myelodysplastic Syndrome (MDS)
    Kim, Sung-Doo
    Choi, Yunsuk
    Park, Young-Hun
    Lee, Jae Seok
    Kim, Dae-Young
    Lee, Jung-Hee
    Lee, Kyoo-Hyung
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Jung, Ah Rang
    Lee, Je-Hwan
    BLOOD, 2011, 118 (21) : 888 - 889
  • [44] The effectiveness of once-daily intravenous busulfan as conditioning for hematopoietic stem cell transplantation in children with acute myelogenous leukemia.
    Park, Seong Shik
    Kim, Seong Heon
    Lim, Young Tak
    BLOOD, 2007, 110 (11) : 313B - 313B
  • [45] PRELIMINARY RESULTS OF NON-ABLATIVE CONDITIONING (NAC) WITH BUSULFAN (Bu), FLUDARABINE (Flu) AND ALEMTUZUMAB FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) TO INDUCE MIXED DONOR CHIMERISM IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
    Bhatia, M.
    Baldinger, L.
    Billote, G.
    Morris, E.
    Bradley, M. B.
    George, D.
    Garvin, J.
    Satwani, P.
    Schwartz, J.
    Wolownik, K.
    Foley, S.
    Hawks, R.
    Baxter-Lowe, L. A.
    Cairo, M. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 82 - 83
  • [46] Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome.
    Conter, Henry Jacob
    Rondon, Gabriela
    Nhu-Nhu Nguyen
    Chen, Julianne
    Shpall, Elizabeth J.
    Khouri, Issa F.
    Giralt, Sergio
    Champlin, Richard E.
    De Lima, Marcos J. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.
    Gurman, Gunhan
    Ataca, Pinar
    Aydin, Tolga
    Atilla, Erden
    Bozdag, Sinem Civriz
    Toprak, Selami Kocak
    Yuksel, Meltem Kurt
    Topcuoglu, Pervin
    Ozcan, Muhit
    Demirer, Taner
    Beksac, Meral
    Ilhan, Osman
    Akan, Hamdi
    Konuk, Nahide
    Arslan, Onder
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
    Kröger, N
    Bornhäuser, M
    Ehninger, G
    Schwerdtfeger, R
    Biersack, H
    Sayer, HG
    Wandt, H
    Schäfer-Eckardt, K
    Beyer, J
    Kiehl, M
    Zander, AR
    ANNALS OF HEMATOLOGY, 2003, 82 (06) : 336 - 342
  • [49] Poor stem cell harvests increase the risk of myelodysplastic syndrome and/or acute myelogenous leukemia (MDS/AML) following autologous stem cell transplant (ASCT)
    Kalaycio, M
    Rybicki, L
    Pohlman, B
    Sobecks, R
    Andresen, S
    Summers, K
    Kuczkowski, E
    Bolwell, BJ
    BLOOD, 2003, 102 (11) : 979A - 979A
  • [50] Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
    N. Kröger
    M. Bornhäuser
    G. Ehninger
    R. Schwerdtfeger
    H. Biersack
    H. G. Sayer
    H. Wandt
    K. Schäfer-Eckardt
    J. Beyer
    M. Kiehl
    A. R. Zander
    Annals of Hematology, 2003, 82 : 336 - 342
12345